Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

224 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.
Danylesko I, Shouval R, Shem-Tov N, Yerushalmi R, Jacoby E, Besser MJ, Shimoni A, Davidson T, Beider K, Mevorach D, Fried S, Nagler A, Avigdor A. Danylesko I, et al. Among authors: yerushalmi r. Bone Marrow Transplant. 2021 May;56(5):1134-1143. doi: 10.1038/s41409-020-01156-y. Epub 2020 Dec 3. Bone Marrow Transplant. 2021. PMID: 33268830 Free PMC article. Clinical Trial.
Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yerushalmi r. Exp Hematol. 2007 Apr;35(4):534-40. doi: 10.1016/j.exphem.2007.01.043. Exp Hematol. 2007. PMID: 17379063 Free article. Clinical Trial.
Comparison between two fludarabine-based reduced-intensity conditioning regimens before allogeneic hematopoietic stem-cell transplantation: fludarabine/melphalan is associated with higher incidence of acute graft-versus-host disease and non-relapse mortality and lower incidence of relapse than fludarabine/busulfan.
Shimoni A, Hardan I, Shem-Tov N, Rand A, Herscovici C, Yerushalmi R, Nagler A. Shimoni A, et al. Among authors: yerushalmi r. Leukemia. 2007 Oct;21(10):2109-16. doi: 10.1038/sj.leu.2404886. Epub 2007 Aug 9. Leukemia. 2007. PMID: 17690701
Ibritumomab tiuxetan (Zevalin) combined with reduced-intensity conditioning and allogeneic stem-cell transplantation (SCT) in patients with chemorefractory non-Hodgkin's lymphoma.
Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Rand A, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A. Shimoni A, et al. Among authors: yerushalmi r. Bone Marrow Transplant. 2008 Feb;41(4):355-61. doi: 10.1038/sj.bmt.1705919. Epub 2007 Nov 19. Bone Marrow Transplant. 2008. PMID: 18026153 Clinical Trial.
Cord blood stem cells for hematopoietic transplantation.
Stanevsky A, Shimoni A, Yerushalmi R, Nagler A. Stanevsky A, et al. Among authors: yerushalmi r. Stem Cell Rev Rep. 2011 Jun;7(2):425-33. doi: 10.1007/s12015-010-9183-9. Stem Cell Rev Rep. 2011. PMID: 20809256 Review.
224 results